ReviewJournal of neuroimaging : official journal of the American Society of Neuroimaging2005
Magnetic resonance spectroscopy in the monitoring of multiple sclerosis.
Review in Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 175 citations in OpenAlex.
- Trial
- A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis.AJNR. American journal of neuroradiology · 2007Trial
- Multimodal Magnetic Resonance Imaging Signatures of White Matter Hyperintensities: Mechanistic Insights Into Pathobiological Heterogeneity.Journal of stroke · 2026Review
- Ultrafast J-resolved magnetic resonance spectroscopic imaging for high-resolution metabolic brain imaging.Nature biomedical engineering · 2025Article
- A rare case of pineal astrocytoma with hemorrhagic changes: Diagnostic and surgical challenges.Radiology case reports · 2025Article
- Article
- Article
- Accelerated 3D metabolite TMagnetic resonance in medicine · 2024Article
- Review
- Article
- Central nervous system involvement in chronic inflammatory demyelinating polyradiculoneuropathy-MRS and DTI study.Frontiers in neurology · 2024Article
- The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?International journal of molecular sciences · 2023Review
- Early metabolic alterations in the normal‑appearing grey and white matter of patients with clinically isolated syndrome suggestive of multiple sclerosis: A proton MR spectroscopic study.Experimental and therapeutic medicine · 2023Article
- Case of elderly onset possible neuro-Behçet's disease with HLA-B51 homozygosity.BMJ case reports · 2023Article
- Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.Radiology · 2022Review
- Current and Future Biomarkers in Multiple Sclerosis.International journal of molecular sciences · 2022Review
- Predictive Value of the Third Ventricle Width for Neurological Status in Multiple Sclerosis.Journal of clinical medicine · 2022Article
- Potential Biomarkers Associated with Multiple Sclerosis Pathology.International journal of molecular sciences · 2021Review
- Differentiation of multiple sclerosis lesions and low-grade brain tumors on MRS data: machine learning approaches.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- What is the optimal schedule for multiparametric MRS? A magnetic resonance fingerprinting perspective.NMR in biomedicine · 2021Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
In addition to providing information on tissue structure, magnetic resonance (MR) technology offers the potential to investigate tissue metabolism and function. MR spectroscopy (MRS) offers a wealth of data on the biochemistry of a selected brain tissue volume, which represent potential surrogate markers for the pathology underlying multiple sclerosis (MS). In particular, the N-acetylaspartate peak in an MR spectrum is a putative marker of neuronal and axonal integrity, and the choline peak appears to reflect cell-membrane metabolism. On this basis, a diminished N-acetylaspartate peak is interpreted to represent neuronal/axonal dysfunction or loss, and an elevated choline peak represents heightened cell-membrane turnover, as seen in demyelination, remyelination, inflammation, or gliosis. Therefore, MRS may provide a unique tool to evaluate the severity of MS, establish a prognosis, follow disease evolution, understand its pathogenesis, and evaluate the efficacy of therapeutic interventions, which complements the information obtained from the various forms of assessment made by conventional MR imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.